Dr. Hersch is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
Neurology Business Group
200 Metro Boulevard
Nutley, NJ 07110Phone+1 201-746-2023
Summary
- Dr. Steven Hersch is a neurologist in Boston, MA and is affiliated with Massachusetts General Hospital, Harvard Medical School. He received his medical degree from Boston University School of Medicine and has been in practice 33 years. He specializes in neurodegenerative disorders and is experienced in memory disorders, movement disorders, and Huntington's disease and in clinical development of experimental therapeutics.
Education & Training
Emory University School of MedicineResidency, Neurology, 1985 - 1990
Boston University School of MedicineClass of 1984
Certifications & Licensure
MA State Medical License 2001 - 2024
ME State Medical License 2021 - 2023
NH State Medical License 2021 - 2023
RI State Medical License 2021 - 2022
GA State Medical License 1987 - 2005- American Board of Psychiatry and Neurology Neurology
Clinical Trials
- Creatine Therapy for Huntington's Disease Start of enrollment: 2001 Oct 01
- Safety and Tolerability Study of Phenylbutyrate in Huntington's Disease (PHEND-HD) Start of enrollment: 2005 Aug 01
- Creatine Safety and Tolerability in Premanifest HD: PRECREST Start of enrollment: 2007 Dec 01
- Join now to see all
Publications & Presentations
PubMed
- 1 citationsCorrection: Updated safety results from phase 3 lecanemab study in early Alzheimer's disease.Lawrence S Honig, Marwan N Sabbagh, Christopher H van Dyck, Reisa A Sperling, Steven Hersch
Alzheimer's Research & Therapy. 2024-07-10 - 15 citationsUpdated safety results from phase 3 lecanemab study in early Alzheimer's disease.Lawrence S Honig, Marwan N Sabbagh, Christopher H van Dyck, Reisa A Sperling, Steven Hersch
Alzheimer's Research & Therapy. 2024-05-10 - 3 citationsThe Vasopressin 1a Receptor Antagonist SRX246 Reduces Aggressive Behavior in Huntington's Disease.Hilda T Maibach, Michael J Brownstein, Steven M Hersch, Karen E Anderson, Debra E Itzkowitz
Journal of Personalized Medicine. 2022-09-22
Journal Articles
- Complex Spatial and Temporally Defined Myelin and Axonal Degeneration in Huntington DiseaseS M Hersch, H D Rosas, ScienceDirect
Press Mentions
Minnesota Farm Couple Raising Sheep to Help in Treating Human DiseaseJune 22nd, 2017
Fearing Punishment for Bad GenesApril 7th, 2014
Assay Shown to Be Effective in Measuring Levels of Mutant Huntingtin ProteinAugust 29th, 2013- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
